Significant reduction of sertraline plasma levels by carbamazepine and phenytoin [2]

European Journal of Clinical Pharmacology

Volumn 57, Issue 12, 2002, Pages 915-916

  Pihlsgård, Maria ^a   Eliasson, Erik ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Carbamazepine; Drug interactions; Sertraline

Indexed keywords

ANTICONVULSIVE AGENT; CARBAMAZEPINE; CYTOCHROME P450; CYTOCHROME P450 3A4; PHENYTOIN; RIFAMPICIN; SERTRALINE;

ANXIETY NEUROSIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG METABOLISM; DRUG MONITORING; DRUG WITHDRAWAL; ENZYME ACTIVITY; EPILEPSY; HUMAN; LETTER; LIVER; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; TREATMENT OUTCOME;

ANTICONVULSANTS; CARBAMAZEPINE; DRUG INTERACTIONS; HUMANS; PHENYTOIN; SEROTONIN UPTAKE INHIBITORS; SERTRALINE;

EID: 0035720196     PISSN: 00316970     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00228-001-0416-3     Document Type: Letter

References (5)

1. The selective serotonin reuptake inhibitor sertraline: Its profile and use in psychiatric disorders
2. Sertraline N-demethylation is catalyzed by multiple isoforms of human cytochrome P-450 in vitro
3. A mechanistic approach to antiepileptic drug interactions
4. Lack of sertraline efficacy probably due to an interaction with carbamazepine
5. Rifampicin-induced selective serotonin reuptake inhibitor withdrawal syndrome in a patient treated with sertraline